

ASPIRE: Advancing access to innovative medicines in low- and middle-income countries



BMS' patient access commitment

ASPIRE: Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity

At Bristol Myers Squibb, our vision to transform patients' lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.

ASPIRE is our company's 10-year strategy to expand access to innovative medicines for patients in low- and middle-income countries (LMICs) to help them live healthier lives.

Addressing health inequities in LMICs

Health inequities continue to persist across the globe, particularly in LMICs, despite the notable progress made in healthcare at large.

The burden of non-communicable diseases (NCDs) is stretching LMIC health systems to new limits, often preventing these nations from providing consistent access to high-quality care and treatments.



LMICs have experienced population growth nearly **four times faster** than high-income nations, now representing 84% of the global population. Although life expectancy of a person living in low-income countries has increased to over 70 years, it is still **18 years less** than that of someone living in high-income countries.



As life expectancy rises, NCDs become more common. According to the World Health Organization, **77% of all NCD-related deaths occur in LMICs.**

Our aspiration to reach more underserved patients

ASPIRE is helping us reach the **bold goals** we have set out to achieve as part of our overarching environmental, social and governance (ESG) strategy, of which access is a key pillar.



Create access plans for **100% of late-stage assets in 2024** – *Complete*



Reach more than **208,000 patients in LMICs per year by 2033** – *In progress*



Provide training support to **1 million healthcare providers by 2033** – *In progress*



BMS has developed tailored approaches to help ensure patients have equitable access to innovative medicines regardless of location or ability to pay



Our expanding commercial presence through regulatory approvals and **Emerging Market Brands (EMBs)** brings our medicines to more countries through a tiered pricing approach.

We have endorsed expansion plans utilizing EMBs in Asia, Latin America, the Middle East, Africa and India with active regulatory filings underway



Our **Innovative Medicine Access Program (BMS-IMAP)** makes our medicines available to patients by request of doctors and medical centers.

We have already made progress with recent institutional agreements in East Africa and will scale to more than 15 LMICs by 2026